Disitamab vedotin, a HER2‐directed antibody‐drug conjugate, in patients with HER2‐overexpression and HER2‐low advanced breast cancer: a phase I/Ib study.

Details

Language :

English

ISSN :

25233548

Volume :

44

Issue :

7

Database :

Complementary Index

Journal :

Cancer Communications

Publication Type :

Academic Journal

Accession number :

178533424

Full Text :

https://doi.org/10.1002/cac2.12577